Hepatoma Research, Journal Year: 2024, Volume and Issue: 10, P. 16 - 16
Published: Jan. 1, 2024
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic disease. This term does not describe pathogenetic mechanisms and complications associated with NAFLD. The new definition, Metabolic Dysfunction-associated Steatotic Liver (MASLD), emphasizes relationship between NAFLD cardiometabolic comorbidities. Cardiovascular features, such as arterial hypertension atherosclerosis, are frequently patients MASLD. Furthermore, these have a high risk developing neoplastic diseases, primarily hepatocellular carcinoma, but also extrahepatic tumors, esophageal, gastric, pancreatic cancers. Moreover, several studies showed correlation MASLD endocrine imbalance gut microbiota, systemic inflammation, obesity, insulin resistance play key role in development complications. narrative review aims to clarify evolution from nomenclature evaluate its
Language: Английский
Citations
13MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options
Current Issues in Molecular Biology, Journal Year: 2024, Volume and Issue: 46(6), P. 5965 - 5983
Published: June 13, 2024
Hepatocellular carcinoma (HCC) represents a significant burden on global healthcare systems due to its considerable incidence and mortality rates. Recent trends indicate an increase in the worldwide of metabolic dysfunction-associated steatotic liver disease (MASLD) shift etiology HCC, with MASLD replacing hepatitis B virus as primary contributor new cases HCC. MASLD-related HCC exhibits distinct characteristics compared viral including unique immune cell profiles resulting overall more immunosuppressive or exhausted tumor microenvironment. Furthermore, is frequently identified older age groups among individuals cardiometabolic comorbidities. Additionally, greater percentage occur noncirrhotic patients those etiologies, hindering early detection. However, current clinical practice guidelines lack specific recommendations for screening patients. The evolving landscape management offers spectrum therapeutic options, ranging from surgical interventions locoregional therapies systemic treatments, across various stages disease. Despite ongoing debates, evidence does not support differences optimal treatment modalities based etiology. In this study, we aimed provide comprehensive overview literature trends, characteristics, implications,
Language: Английский
Citations
7Muscle Strength and Cardiovascular Health in MASLD: A Prospective Study
Medicina, Journal Year: 2025, Volume and Issue: 61(2), P. 247 - 247
Published: Feb. 1, 2025
Background and Objectives: The pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD) remains incompletely understood. However, recent studies highlight the interactions between muscle, liver, adipose tissue. This study aimed to explore relationships clinical indicators MASLD sarcopenia, cardiorespiratory fitness, fatigue, mood. Materials Methods: involved 60 participants, including 28 healthy controls 32 with MASLD, categorized into two subgroups: 15 MASL 17 steatohepatitis (MASH). Participants completed an incremental speed shuttle walk test evaluate a hand-held dynamometer assessment for appendicular muscle strength, timed up go physical performance. Physical activity level, quality life, emotional state were assessed using questionnaires. results compared groups characteristics. Results: MASH showed reduced fitness (p < 0.001). knee extensors significantly weaker in both 0.001 p = 0.001, respectively). group reported higher levels depression negative health perception 0.006 0.03, Muscle strength patients significant association (OR −0.384, 95% CI: −3.10 −0.74, 0.003), intrahepatic triglyceride content −0.287, −1.31 −0.11, 0.023), LDL −0.286, −0.02 −0.33, 0.03). In contrast, positive was observed VO2 0.531, CI 1.27 3.47, Conclusions: suggests that is linked key parameters, such as hepatic fat, levels, aerobic capacity, may contribute development progression MASLD. Interventions at preserving or enhancing be essential preventing damage improving health.
Language: Английский
Citations
0Metabolic dysfunction associated fatty liver disease in healthy weight individuals
Hepatology International, Journal Year: 2024, Volume and Issue: 18(S2), P. 884 - 896
Published: July 25, 2024
Metabolic dysfunction associated fatty liver disease (MAFLD) is an increasing public health problem, affecting one third of the global population. Contrary to conventional wisdom, MAFLD not exclusive obese or overweight individuals. Epidemiological studies have revealed a remarkable prevalence among healthy weight individuals, leading investigations into genetic, lifestyle, and dietary factors that contribute development in this This shift perspective requires reconsideration preventive strategies, diagnostic criteria therapeutic approaches tailored address unique characteristics It also underscores importance widespread awareness education, within medical community general population, promote more inclusive understanding metabolic disorders. With review, we aim provide comprehensive exploration encompassing epidemiological, pathophysiological, clinical aspects.
Language: Английский
Citations
3A New Classification System for Fatty Liver—What Sonographers Should Know
Sonography, Journal Year: 2025, Volume and Issue: unknown
Published: April 23, 2025
ABSTRACT Hepatic steatosis or fatty liver disease is a rapidly emerging health issue and closely linked to an increase in cardiometabolic conditions such as obesity type 2 diabetes. The nomenclature surrounding has recently undergone multiple reviews better reflect its underlying causes. This article recent guidelines changes will explore the various ultrasound technologies that are available for fat quantification, emphasising ultrasound's importance diagnosing monitoring steatosis. Sonographers must remain informed of classification criteria they directly impact their role detecting assessing
Language: Английский
Citations
0Hepatokines and MASLD: The GLP1-Ras-FGF21-Fetuin-A Crosstalk as a Therapeutic Target
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(19), P. 10795 - 10795
Published: Oct. 8, 2024
The introduction of the term “Metabolic Steatotic Liver Disease” (MASLD) underscores critical role metabolic dysfunction in development and progression chronic liver disease emphasizes need for strategies that address both its comorbidities. In recent years, a liver-focused perspective has revealed altered endocrine function fatty is key contributor to dysregulation observed MASLD. Due secretory capacity, liver’s increased production proteins known as “hepatokines” been linked insulin resistance, explaining why MASLD often precedes other organs ultimately contributes systemic disease. Among these hepatokines, fibroblast growth factor 21 (FGF21) fetuin-A play central roles regulating abnormalities associated with MASLD, their dysregulated secretion response stress implicated This review postulates modulation by GLP1-Ras may mediate beneficial effects drugs, which have attention emerging pharmacotherapy By discussing crosstalk between GLP1-Ras-FGF21-fetuin-A, this hypothesizes possible novel GLP1-FGF21 dual agonist contribute management diseases. Although research needed go into details crosstalk, topic help researchers explore mechanisms type manage
Language: Английский
Citations
2Mechanisms of Metal-Induced Hepatic Inflammation
Current Environmental Health Reports, Journal Year: 2024, Volume and Issue: 11(4), P. 547 - 556
Published: Nov. 5, 2024
Language: Английский
Citations
0Impact of Liver Disease on Use of Muscle Relaxants in Anesthesia: A Comprehensive Review
Medical Science Monitor, Journal Year: 2024, Volume and Issue: 30
Published: Nov. 19, 2024
Skeletal muscle relaxants have found wide application in anesthesiology.They are used during surgeries, to support mechanical ventilation, or as an aid for safe intubation.Their use is associated with the creation of a conduction block at neuromuscular junction.To terminate blockade prevent residual blockade, another group drugs called reversal agents used.These include like neostigmine and sugammadex.Many factors may influence duration potency skeletal relaxants, including dysfunctions organs such kidneys liver.Liver damage can various etiologies -it be toxic drug-induced, due ingestion substances, viral infections, alcohol consumption.In recent years, there been increasing reports on impact metabolic disorders liver steatosis damage.The responsible metabolism many drugs, excretion metabolites into bile, protein production.Progressive lead its remodeling, eventually cirrhosis failure.Liver dysfunction numerous systemic complications.A decrease synthesis causes binding plasma proteins, volume distribution, increased amount free drug forms body.Liver failure affect some agents.This article aims review role anesthesia patents disease.
Language: Английский
Citations
0Revolutionizing the understanding of liver disease: Metabolism, function and future
World Journal of Hepatology, Journal Year: 2024, Volume and Issue: 16(12), P. 1365 - 1370
Published: Nov. 29, 2024
The intersection between metabolic-associated steatotic liver disease (MASLD) and chronic hepatitis B virus (HBV) infection is an emerging area of research with significant implications for public health clinical practice. Wang
Language: Английский
Citations
0Introduction of MASLD
Published: Jan. 1, 2024
Language: Английский
Citations
0